Clenbuterol

Generic Name
Clenbuterol
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C12H18Cl2N2O
CAS Number
37148-27-9
Unique Ingredient Identifier
XTZ6AXU7KN
Background

A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.

Indication

Used as a bronchodilator in the treatment of asthma patients.

Associated Conditions
Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Lung Disorder
Associated Therapies
-
Clinical Trials
Related News

Clenbuterol to Target DUX4 in FSHD

Phase 1
Not yet recruiting
Conditions
Muscular Dystrophy, Facioscapulohumeral
Interventions
Drug: Clenbuterol
First Posted Date
2024-12-06
Last Posted Date
2024-12-06
Lead Sponsor
Jeffrey Statland
Target Recruit Count
30
Registration Number
NCT06721299
Locations
🇺🇸

University of Kansas Medical Center, Kansas City, Kansas, United States

🇺🇸

University of Rochester Medical Center, Rochester, New York, United States

🇺🇸

University of Washington, Seattle, Washington, United States

A Placebo-controlled Study of Clenbuterol in Spinal and Bulbar Muscular Atrophy

First Posted Date
2023-12-13
Last Posted Date
2024-04-15
Lead Sponsor
Gianni Soraru
Target Recruit Count
90
Registration Number
NCT06169046
Locations
🇮🇹

Azienda Ospedale Università di Padova, Padova, PD, Italy

Muscle Memory After Treatment With Anabolic Substance Clenbuterol and Resistance Training in Humans

Not Applicable
Recruiting
Conditions
Skeletal Muscle Physiology
Interventions
Drug: Placebo
Drug: Clenbuterol
First Posted Date
2023-01-20
Last Posted Date
2023-01-20
Lead Sponsor
Morten Hostrup, PhD
Target Recruit Count
60
Registration Number
NCT05692856
Locations
🇩🇰

August Krogh Building, Copenhagen, Denmark

Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral Sclerosis

Phase 2
Completed
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Drug: Clenbuterol
First Posted Date
2020-01-29
Last Posted Date
2022-09-06
Lead Sponsor
Dwight Koeberl, M.D., Ph.D.
Target Recruit Count
25
Registration Number
NCT04245709
Locations
🇺🇸

Duke University Medical center, Durham, North Carolina, United States

Phase II Clinical Trial of Clenbuterol in Adult Patients With Pompe Disease

Phase 2
Withdrawn
Conditions
Pompe Disease (Late-onset)
Interventions
Drug: Placebos
Drug: Clenbuterol
First Posted Date
2019-09-19
Last Posted Date
2022-08-17
Lead Sponsor
Duke University
Registration Number
NCT04094948
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

cAMP Signaling and Muscle Adaptations

First Posted Date
2015-09-23
Last Posted Date
2017-10-26
Lead Sponsor
University of Copenhagen
Target Recruit Count
72
Registration Number
NCT02557581
Locations
🇩🇰

Bispebjerg University Hospital, Copenhagen, Denmark

🇩🇰

Department of Nutrition, Exercise and Sports, Copenhagen, Denmark

Safety and Efficacy of Clenbuterol in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy

Phase 1
Completed
Conditions
Pompe Disease
Interventions
Drug: Placebo
Drug: Clenbuterol
First Posted Date
2013-09-16
Last Posted Date
2019-07-02
Lead Sponsor
Dwight Koeberl, M.D., Ph.D.
Target Recruit Count
17
Registration Number
NCT01942590
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure

Phase 1
Terminated
Conditions
Dilated Cardiomyopathy
Heart Failure
Interventions
Drug: clenbuterol
First Posted Date
2008-01-03
Last Posted Date
2017-12-15
Lead Sponsor
Francis D. Pagani
Target Recruit Count
18
Registration Number
NCT00585546
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

🇺🇸

Ohio State University, Columbus, Ohio, United States

🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 4 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy